SCHEMBL26075656

SCHEMBL26075656

CC(C)(C)c1ccc(C(=O)Nc2cc(C(F)(F)F)ccc2F)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.62
NR1H4 Q96RI1 1/20 0.62
TRPV1 Q8NER1 1/20 0.61
TMPRSS4 Q9NRS4 1/20 0.58
KMT2A Q03164 4/20 0.53
MEN1 O00255 3/20 0.53
TSHR P16473 1/20 0.53
MAPK14 Q16539 1/20 0.53
SERPINE1 P05121 1/20 0.52
KDM4E B2RXH2 3/20 0.52
MAPT P10636 3/20 0.52
HTT P42858 1/20 0.52
ALDH1A1 P00352 3/20 0.51
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
PTGS1 P23219 1/20 0.51
GLA P06280 1/20 0.51
ATM Q13315 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25226228 0.85 CYP1A2 (0.58) TMPRSS4KMT2AMEN1TSHRKDM4E
SCHEMBL26074394 0.85 ALDH1A1 (0.66) PPARGNR1H4KMT2AMEN1MAPK14
SCHEMBL2951980 0.82 MTOR (0.58) TMPRSS4KMT2AMEN1TSHRMAPK14
SCHEMBL22024996 0.82 GAA (0.51) PPARGNR1H4TMPRSS4KMT2AMEN1
SCHEMBL15652931 0.82 NR1H4 (0.58) PPARGNR1H4TRPV1KMT2AMEN1
SCHEMBL22025009 0.81 PTGS1 (0.54) TMPRSS4KMT2AMEN1TSHRKDM4E
SCHEMBL22065213 0.81 GAA (0.53) PPARGNR1H4TMPRSS4KMT2AMEN1
SCHEMBL2949476 0.80 TMPRSS4 (0.53) PPARGNR1H4TMPRSS4KMT2AMEN1
SCHEMBL19669082 0.80 MEN1 (0.57) TRPV1TMPRSS4KMT2AMEN1TSHR
SCHEMBL18205840 0.80 MEN1 (0.57) PPARGNR1H4TRPV1TMPRSS4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORP (US) 2023-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ERBB2, ERBB3, ERBB4 PPARG 2458/4885NR1H4 2474/4885TRPV1 4187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.